0.6091

4.05% 0.0237

After Hours: .58 -0.0291 -4.78%

Jasper Therapeutics Inc (JSPR)

Overview News Price History Option Chain Financials Discussions Forecast

Jasper Therapeutics Inc stock is traded at $0.6091, with a volume of 163.09K. It is up +4.05% in the last 24 hours and down -15.43% over the past month. Jasper Therapeutics Inc is a clinical-stage biotechnology company focused on developing therapeutics targeting mast cell driven diseases such as Chronic Spontaneous Urticaria (CSU), Chronic Inducible Urticaria (CIndU) and asthma. The company's lead product candidate, briquilimab, is a monoclonal antibody designed to block stem cell factor (SCF) from binding to and signaling through the CD117 (KIT) receptor on mast and stem cells. The company has a single operating and reportable segment, which is the research and development of therapeutic products in the fields of chronic urticaria and asthma.

Previous Close:

$0.5854

Open:

$0.592501

24h Volume:

163.09K

Relative Volume:

0.15

Market Cap:

$20.27M

Revenue:

Net Income/Loss:

$-55.73M

P/E Ratio:

-0.1887

EPS:

-3.2274

Net Cash Flow:

$-68.87M

1W Performance:

-1.41%

1M Performance:

-15.43%

6M Performance:

-44.12%

1Y Performance:

-73.86%

1-Day Range:

$0.5787

$0.6199

1-Week Range:

$0.5443

$0.6698

52-Week Range:

$0.3151

$2.69

Jasper Therapeutics Inc Stock (JSPR) Company Profile

Name

Jasper Therapeutics Inc

Sector

Healthcare (1067)

Industry

Biotechnology (595)

Phone

(650) 549-1400

Address

2200 BRIDGE PKWY SUITE #102, REDWOOD CITY

Employee

Twitter

Next Earnings Date

2026-11-09

Latest SEC Filings

JSPR's Discussions on Twitter

Compare JSPR vs VRTX, REGN, MRNA, ARGX, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
JSPR Jasper Therapeutics Inc	0.6091	19.48M	0	-55.73M	-68.87M	-3.2274
VRTX Vertex Pharmaceuticals Inc	526.19	132.40B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	788.04	81.95B	14.92B	4.42B	3.79B	41.04
MRNA Moderna Inc	198.88	77.78B	2.23B	-3.19B	-1.60B	-8.1462
ARGX Argen X Se Adr	959.49	60.20B	4.16B	1.29B	734.26M	19.58
RVMD Revolution Medicines Inc	204.97	42.84B	742.00K	-1.37B	-1.07B	-7.0731

Jasper Therapeutics Inc Stock (JSPR) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Mar-23-26	Resumed	UBS	Neutral
Jan-13-26	Initiated	Rodman & Renshaw	Buy
Jul-08-25	Downgrade	BMO Capital Markets	Outperform → Market Perform
Jul-08-25	Downgrade	RBC Capital Mkts	Outperform → Sector Perform
Jul-07-25	Downgrade	Cantor Fitzgerald	Overweight → Neutral
Jul-07-25	Downgrade	William Blair	Outperform → Mkt Perform
Feb-13-25	Initiated	UBS	Buy
Dec-06-24	Initiated	BMO Capital Markets	Outperform
Sep-09-24	Initiated	JMP Securities	Mkt Outperform
Jul-08-24	Initiated	BTIG Research	Buy
Jun-27-24	Initiated	Stifel	Buy
May-06-24	Initiated	H.C. Wainwright	Buy
Apr-03-24	Initiated	Evercore ISI	Outperform
Mar-28-24	Initiated	RBC Capital Mkts	Outperform
Mar-18-24	Initiated	TD Cowen	Outperform
Aug-11-23	Initiated	CapitalOne	Overweight
Feb-28-22	Initiated	Cantor Fitzgerald	Overweight
Nov-08-21	Initiated	Credit Suisse	Outperform
Oct-21-21	Initiated	William Blair	Outperform
Oct-20-21	Initiated	BMO Capital Markets	Outperform
Oct-13-21	Initiated	Oppenheimer	Outperform

View All

Jasper Therapeutics Inc Stock (JSPR) Latest News

Sep 24, 2026

Ten Jasper Therapeutics (JSPR) warrants are exercisable for one share as Nasdaq moves to remove their listing. - Stock Titan

Sep 24, 2026

Jasper Therapeutics stock gains 1.39 percent on Nasdaq - AD HOC NEWS

Sep 24, 2026

Sep 22, 2026

Jasper Therapeutics stock holds at USD 5.42 as pipeline data guide trading - AD HOC NEWS

Sep 22, 2026

Sep 21, 2026

Jasper Therapeutics stock holds recent gains as investors watch latest trial and funding data - AD HOC NEWS

Sep 21, 2026

Sep 17, 2026

Jasper Therapeutics, Inc.(NasdaqCM: JSPR) added to NASDAQ Composite Index - marketscreener.com

Sep 17, 2026

Sep 16, 2026

JSPR: Merger yields robust pipeline and funding, with major clinical and regulatory milestones ahead - TradingView

Sep 16, 2026

Jasper Therapeutics at H.C. Wainwright: cash and catalysts By Investing.com - Investing.com Canada

Sep 16, 2026

JSPR: Merger creates a robust immunology pipeline with major clinical and regulatory milestones ahead - TradingView

Sep 16, 2026

Sep 15, 2026

Jasper Therapeutics appoints two executives to key roles By Investing.com - Investing.com Australia

Sep 15, 2026

Jasper Therapeutics appoints two executives to key roles - Investing.com

Sep 15, 2026

Jasper Therapeutics Announces Key Regulatory and Clinical Appointments - Yahoo Finance

Sep 15, 2026

Sep 09, 2026

A biotech company's New York talk will be webcast live - Stock Titan

Sep 09, 2026

Sep 08, 2026

Jasper Therapeutics (NASDAQ: JSPR) Schedules September 30 Vote on Increasing Authorized Common Stock - kalkinemedia.com

Sep 08, 2026

Sep 02, 2026

12 Health Care Stocks Moving In Wednesday's Pre-Market Session - Benzinga

Sep 02, 2026

Aug 28, 2026